Want to see PPBT full AI Analyst Report?
Purple Biotech (PPBT) Ratios
Purple Biotech Ratios
PPBT's free cash flow for Q2 2026 was $-2.51M. For the 2026 fiscal year, PPBT's free cash flow was increased by $0.00 and operating cash flow was $-2.50M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.27 | 2.23 | 2.20 | 4.71 | 11.41 |
| Quick Ratio | 1.27 | 2.23 | 2.20 | 4.71 | 11.41 |
| Cash Ratio | 1.12 | 1.86 | 2.02 | 2.13 | 2.56 |
| Solvency Ratio | -3.31 | -1.71 | 0.00 | -2.85 | -3.57 |
| Operating Cash Flow Ratio | -0.71 | -3.60 | -2.77 | -2.37 | -3.55 |
| Short-Term Operating Cash Flow Coverage | 0.00 | -78.51 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 1.95M | $ 4.78M | $ 5.78M | $ 25.73M | $ 43.38M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.00 | 0.01 | 0.01 | 0.01 |
| Debt-to-Equity Ratio | 0.03 | 0.01 | 0.01 | 0.01 | 0.01 |
| Debt-to-Capital Ratio | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.81 | 1.13 | 1.30 | 1.16 | 1.08 |
| Debt Service Coverage Ratio | -673.08 | -11.19 | -9.11 | -320.78 | -82.62 |
| Interest Coverage Ratio | -704.05 | -24.62 | -10.21 | -337.36 | -84.59 |
| Debt to Market Cap | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.06 | 3.84 | 2.06 | 0.63 | 1.08 |
| Net Debt to EBITDA | 0.32 | 1.02 | 0.71 | 0.68 | 0.58 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | -0.10% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | -10173.95% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | -10150.46% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | -11374.13% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | -10202.55% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | -10.15% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | -10202.55% | 0.00% | 0.00% |
| Net Income Per EBT | 99.60% | 99.46% | 0.10% | 99.58% | 103.13% |
| EBT Per EBIT | 96.48% | 66.14% | 89.70% | 96.27% | 99.40% |
| Return on Assets (ROA) | -150.16% | -19.55% | -0.04% | -39.67% | -26.19% |
| Return on Equity (ROE) | -271.63% | -22.03% | -0.06% | -46.19% | -28.36% |
| Return on Capital Employed (ROCE) | -279.65% | -33.30% | -60.00% | -47.52% | -27.19% |
| Return on Invested Capital (ROIC) | -272.87% | -32.93% | -59.70% | -47.33% | -27.11% |
| Return on Tangible Assets | -258.39% | -78.73% | -0.12% | -63.85% | -36.98% |
| Earnings Yield | -83.66% | -94.15% | -0.10% | -84.96% | -26.55% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.13 | 0.06 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.42 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -2855.24 | -6577.45 | -6484833.33 | -9775363.64 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 2855.24 | 6577.45 | 6484833.33 | 9775363.64 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.15 | -87.63 | -16.19 | -18.11 | -16.93 |
| Free Cash Flow Per Share | -1.15 | -87.63 | -16.19 | -18.36 | -17.06 |
| Dividend Paid and CapEx Coverage Ratio | -1830.27 | 0.00 | -6641.67 | -73.40 | -131.05 |
| Capital Expenditure Coverage Ratio | -1830.27 | 0.00 | -6641.67 | -73.40 | -131.05 |
| Operating Cash Flow Coverage Ratio | -22.69 | -78.51 | -56.77 | -32.50 | -20.12 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | -101.76 | 0.00 | 0.00 |
| Free Cash Flow Yield | -17.56% | -186.84% | -105.05% | -66.51% | -21.93% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.19 | -1.06 | -954.19 | -1.18 | -3.77 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 96.88 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 3.25 | 0.23 | 0.55 | 0.54 | 1.07 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -5.69 | -0.54 | -0.95 | -1.50 | -4.56 |
| Price-to-Operating Cash Flow Ratio | -5.70 | -0.54 | -0.95 | -1.52 | -4.59 |
| Price-to-Earnings Growth (PEG) Ratio | -0.05 | 0.01 | 34.35 | -0.18 | 0.10 |
| Enterprise Value Multiple | -0.88 | -0.07 | -0.24 | -0.51 | -3.37 |
| Enterprise Value | 23.07M | 471.56K | 4.83M | 10.99M | 59.10M |
| EV to EBITDA | -0.88 | -0.07 | -0.24 | -0.51 | -3.37 |
| EV to Sales | 0.00 | 0.00 | 24.67 | 0.00 | 0.00 |
| EV to Free Cash Flow | -4.16 | -0.03 | -0.24 | -0.65 | -3.89 |
| EV to Operating Cash Flow | -4.17 | -0.03 | -0.24 | -0.66 | -3.92 |
| Tangible Book Value Per Share | 0.48 | 30.92 | 5.08 | 28.58 | 50.14 |
| Shareholders’ Equity Per Share | 2.02 | 200.42 | 27.79 | 50.77 | 72.84 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.16 | 0.00 | 0.00 |
| Net Income Per Share | -5.50 | -44.16 | -0.02 | -23.45 | -20.66 |
| Tax Burden | 1.00 | 0.99 | 0.00 | 1.00 | 1.03 |
| Interest Burden | 1.00 | 1.01 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 87.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 24.74 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 9.58 | 0.00 | 0.00 |
| Income Quality | 0.21 | 1.97 | 1.00 | 0.77 | 0.85 |
Currency in USD
